Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

被引：141

作者：

Piper-Vallillo, Andrew J. ^{[1
,2
,3
]}

Sequist, Lecia, V ^{[2
,3
]}

Piotrowska, Zofia ^{[2
,3
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Med Oncol, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 25期

关键词：

TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; 1ST-LINE ERLOTINIB; BRAIN METASTASES; OPEN-LABEL; MUTATION; THERAPY; COMBINATION; CRIZOTINIB; ADENOCARCINOMA;

D O I：

10.1200/JCO.19.03123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advancedEGFR-mutant non -small cell lung cancer (NSCLC). Understanding osimertinib resistance mechanisms and currently available treatment options are essential to selecting optimal second line therapy for patients whose disease progresses during front-line osimertinib. Using data compiled from 6 osimertinib-resistance series, we describe here the heterogeneous profile of EGFR-dependent and independent mechanisms of osimertinib treatment failure. We identifiedMETalterations (7%-24%),EGFRC797X (0%-29%), SCLC transformation (2%-15%), and oncogene fusions (1%-10%) as the most common mechanisms of resistance. This review provides an evidence-based, algorithmic approach to the evaluation and management of post-osimertinib progression as well as a compendium of active, enrolling clinical trials for this population.

引用

页码：2926 / +

页数：13

共 90 条

[61] An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib [J].

Sato, Mitsuo ;

Matsui, Akira ;

Shimoyama, Yoshie ;

Omote, Norihito ;

Morise, Masahiro ;

Hase, Tetsunari ;

Tanaka, Ichidai ;

Suzuki, Kojiro ;

Hasegawa, Yoshinori .

INTERNAL MEDICINE, 2018, 57 (23) :3429-3432

[62] EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung [J].

Scher, Kevin S. ;

Saldivar, Juan-Sebastian ;

Fishbein, Michael ;

Marchevsky, Alberto ;

Reckamp, Karen L. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (09) :1040-1044

[63] Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib [J].

Schoenfeld, A. J. ;

Arbour, K. C. ;

Rizvi, H. ;

Iqbal, A. N. ;

Gadgeel, S. M. ;

Girshman, J. ;

Kris, M. G. ;

Riely, G. J. ;

Yu, H. A. ;

Hellmann, M. D. .

ANNALS OF ONCOLOGY, 2019, 30 (05) :839-844

[64]

Schoenfeld AJ, 2020, CLIN CANCER RES, V26, P2654, DOI [10.1158/10780432.CCR-19-3563, 10.1158/1078-0432.CCR-19-3563]

[65] Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases [J].

Seoane, J. ;

De Mattos-Arruda, L. ;

Le Rhun, E. ;

Bardelli, A. ;

Weller, M. .

ANNALS OF ONCOLOGY, 2019, 30 (02) :211-218

[66] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J].

Sequist, Lecia V. ;

Yang, James Chih-Hsin ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Hirsh, Vera ;

Mok, Tony ;

Geater, Sarayut Lucien ;

Orlov, Sergey ;

Tsai, Chun-Ming ;

Boyer, Michael ;

Su, Wu-Chou ;

Bennouna, Jaafar ;

Kato, Terufumi ;

Gorbunova, Vera ;

Lee, Ki Hyeong ;

Shah, Riyaz ;

Massey, Dan ;

Zazulina, Victoria ;

Shahidi, Mehdi ;

Schuler, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3327-+

[67] Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors [J].

Sequist, Lecia V. ;

Waltman, Belinda A. ;

Dias-Santagata, Dora ;

Digumarthy, Subba ;

Turke, Alexa B. ;

Fidias, Panos ;

Bergethon, Kristin ;

Shaw, Alice T. ;

Gettinger, Scott ;

Cosper, Arjola K. ;

Akhavanfard, Sara ;

Heist, Rebecca S. ;

Temel, Jennifer ;

Christensen, James G. ;

Wain, John C. ;

Lynch, Thomas J. ;

Vernovsky, Kathy ;

Mark, Eugene J. ;

Lanuti, Michael ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (75)

[68] Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC [J].

Shah, Khyati N. ;

Bhatt, Roma ;

Rotow, Julia ;

Rohrberg, Julia ;

Olivas, Victor ;

Wang, Victoria E. ;

Kuhn, Jonathan ;

Dumont, Sophie ;

Mccormick, Frank ;

Goga, Andrei ;

Blakely, Collin M. ;

Bivona, Trever G. ;

Bandyopadhyay, Sourav .

CANCER RESEARCH, 2019, 79 (13)

[69] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

[70] EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: A systematic review and meta-analysis [J].

Soon, Yu Yang ;

Leong, Cheng Nang ;

Koh, Wee Yao ;

Tham, Ivan Weng Keong .

RADIOTHERAPY AND ONCOLOGY, 2015, 114 (02) :167-172

← 1 2 3 4 5 6 7 8 9 →